Clik here to view.
Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after...
Aerium Therapeutics has ceased operations, ending its mission to bring to market new antibodies to protect immunocompromised people from Covid-19, develop highly sought-after long Covid treatments and...
View ArticleBioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets
Plus, news about Tenax Therapeutics: BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the market.” The company tried to...
View ArticleClik here to view.
Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B
Eisai is paying SEED Therapeutics an undisclosed amount upfront in a deal worth up to $1.5 billion to develop new ‘molecular glue’-based therapies for neurodegenerative diseases and cancer. The...
View ArticleBicycle Therapeutics focuses pipeline and streamlines leadership team
Bicycle Therapeutics spelled out its pipeline priorities on Tuesday, adding that it will be looking for collaborators for its immune-oncology pipeline. It is also narrowing its executive team. The...
View ArticleGSK wins second Zantac cancer case to go to trial
GSK was found not liable in the second jury trial involving the company’s heartburn medication, Zantac. The company said in a statement Monday that the decision in Illinois state court is “consistent...
View ArticleClik here to view.
TPG reveals $580M life sciences fund, which has already backed multiple biotechs
Another large asset manager is further boosting its presence in the biotech and life sciences with a large fund for startups. The private equity manager TPG said Tuesday morning it closed a $580...
View ArticleNovo Nordisk goes after more compounders, expanding GLP-1 lawsuit campaign
Novo Nordisk is turning up the heat on compounding pharmacies making versions of its blockbuster. Late last week, the company filed 11 new lawsuits against med spas, weight loss clinics and telehealth...
View ArticleClik here to view.
CDC chief says new RSV guidance was meant to be ‘clear’ and ‘actionable’
CDC Director Mandy Cohen says that new guidance for respiratory syncytial virus (RSV) vaccination was meant to be easier to implement than last year’s advice, explaining some of the thinking behind a...
View ArticleUpdated: Amgen's Horizon buyout powers growth, with MariTide plans intact
Amgen’s Horizon deal is starting to pay off, as the biotech giant reported a 20% increase in quarterly revenue compared with the year prior. In total, Amgen reported sales of $8.4 billion, about $1...
View ArticleUpdated: FDA approves Servier’s brain cancer drug, setting up $1B payout for...
The FDA approved a new treatment for a rare form of brain cancer whose tumors have a mutation that drives the disease. Tuesday’s approval of the drug, known as vorasidenib, was granted to Servier...
View ArticleClik here to view.
Precigen lays off staff, pauses multiple CAR-T programs and all preclinical...
Maryland biotech Precigen said it will lay off more than 20% of its workforce, pause multiple CAR-T clinical programs, halt all preclinical R&D, and try to raise $30 million in a public offering....
View ArticleClik here to view.
Weak China demand weighs on Illumina's sales
Illumina’s sales dropped in the second quarter, dragged down by weak demand in China and the company shipping fewer of its mid-throughput DNA sequencers than expected. The company is among the most...
View ArticleNovo Nordisk yanks Wegovy filing for heart failure from FDA, will resubmit...
Novo Nordisk is running into a speed bump with Wegovy’s label expansion efforts in heart disease as it has pulled its FDA submission in heart failure with obesity and will refile at the start of 2025....
View ArticleExelixis’ Cabometyx misses survival endpoint, but will still file in prostate...
Exelixis’ second-quarter earnings report revealed a primary endpoint statistical significance failure, a potential market launch into a new indication and an ADC cut. Despite Cabometyx plus Merck’s...
View ArticleNovo Nordisk doubles US Wegovy prescriptions as shortages start to ease, but...
Nearly all of Novo Nordisk’s blockbuster GLP-1 Wegovy and Ozempic drugs have been taken off the FDA shortage list as the company reports a doubling of prescriptions in the US since the beginning of the...
View ArticleUpdated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra
Madrigal Pharmaceuticals is “off to a strong start” with its recently approved MASH drug Rezdiffra, CEO Bill Sibold said on Wednesday. The company pulled $14.6 million in the first full quarter of...
View ArticleClik here to view.
Private Danish iron deficiency biotech to buy G1 Therapeutics for $405M
A decades-old, relatively unknown private biotech focused on iron deficiency is buying a commercial-stage oncology company nestled in North Carolina. Holbæk, Denmark-headquartered Pharmacosmos will...
View ArticleClik here to view.
Inspection delays hold back BeiGene's Tevimbra progress once again
BeiGene will need to wait a bit longer for an FDA decision on cancer immunotherapy, Tevimbra, citing a delay in scheduling clinical site inspections. The disclosure, included in BeiGene’s...
View ArticlePfizer invests $98M in Australian manufacturing to help develop new...
Pfizer has allocated 150 million Australian dollars (around $98 million) to install upgrades and build a new manufacturing facility at its existing site in Melbourne in an effort to advance new...
View ArticlePfizer got a $1.2B payout for its stake in Cerevel
AbbVie’s $8.7 billion deal for Cerevel has led to a significant payout for Pfizer. Pfizer created Cerevel with Bain Capital in 2018, spinning out several neuroscience assets into the new company. It...
View Article